Currently, three different BRAF/MEKi combinations have demonstrated an ORR of 64–69% and a 5-year OS rate of approximately 34% in their pivotal trials, all of which have been approved by the FDA and EMA in the setting of advanced melanoma. This evidence concerns the gene BRAF and melanoma.